Literature DB >> 7875190

Individualized drug utilization statistics. Analysing a population's drug use from the perspective of individual users.

J Hallas1, A Nissen.   

Abstract

The Danish retail pharmacies' drug subsidy system is completely computerized. The data are person-identifiable, making it possible to chart the population's drug use from the perspective of individual users. We decided to explore the potential of this data source and to analyse heavy drug users specifically. The analysis encompassed all 890,352 prescriptions presented by citizens of Odense in 1991. There was a total sales volume of 32 million defined daily doses consumed by 113,468 adult drug users, corresponding to 65.1% of the adult population. We found 2388 heavy drug users, defined by an annual purchase of more than 2000 defined daily doses. Heavy drug users accounted for 1.4% of the adult population and 22.9% of drug sales. They were remarkably well characterized by their main therapeutic class, which constituted a median of 47% of their drug use. A median of 97% of each heavy user's drugs were issued by one main prescriber. We conclude that heavy drug use can generally be ascribed to severe disease rather than to irresponsible prescribing. For the most important drug classes, we present various epidemiological measures of drug use, including 1-year prevalence, incidence, duration of therapy and some measures of skewness in utilization. If analysed regularly these measures can disclose subtle trends in clinical drug use that would not be evident from the wholesale figures.

Entities:  

Mesh:

Year:  1994        PMID: 7875190     DOI: 10.1007/bf00191170

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  FARMAGUIDA: a databank for the analysis of the Italian drug market and drug utilization in general practice.

Authors:  N Montanaro; A Vaccheri; N Magrini; M Battilana
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics.

Authors:  E F Juniper; P A Kline; M A Vanzieleghem; E H Ramsdale; P M O'Byrne; F E Hargreave
Journal:  Am Rev Respir Dis       Date:  1990-10

3.  Drug utilization studies. Methods and uses. Introduction.

Authors:  M N Dukes
Journal:  WHO Reg Publ Eur Ser       Date:  1993

4.  Utilization of antihypertensive drugs in certain European countries.

Authors:  D Capellà; M Porta; J R Laporte
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma.

Authors:  T Haahtela; M Järvinen; T Kava; K Kiviranta; S Koskinen; K Lehtonen; K Nikander; T Persson; K Reinikainen; O Selroos
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

6.  Individual utilization of anti-asthma medication by young adults: a prescription database analysis.

Authors:  J Hallas; N C Hansen
Journal:  J Intern Med       Date:  1993-07       Impact factor: 8.989

7.  The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988.

Authors:  P Hörnsten; M Keisu; B E Wiholm
Journal:  Arch Dermatol       Date:  1990-07

8.  Epidemiological studies of diabetes mellitus in Denmark. II. A prevalence study based on insulin prescriptions.

Authors:  A Green; M Hauge; N V Holm; L L Rasch
Journal:  Diabetologia       Date:  1981-04       Impact factor: 10.122

Review 9.  Impact of drug use evaluation upon ambulatory pharmacy practice.

Authors:  E P Armstrong; A K Terry
Journal:  Ann Pharmacother       Date:  1992-12       Impact factor: 3.154

10.  Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis.

Authors:  C M Callahan; R S Dittus; B P Katz
Journal:  Ann Intern Med       Date:  1991-02-01       Impact factor: 25.391

View more
  7 in total

Review 1.  Abuse Potential of Pregabalin: A Systematic Review.

Authors:  Ole Schjerning; Mary Rosenzweig; Anton Pottegård; Per Damkier; Jimmi Nielsen
Journal:  CNS Drugs       Date:  2016-01       Impact factor: 5.749

2.  Comparison of indicators assessing the quality of drug prescribing for asthma.

Authors:  C C Veninga; P Denig; L G Pont; F M Haaijer-Ruskamp
Journal:  Health Serv Res       Date:  2001-04       Impact factor: 3.402

3.  Drug expenditure of high-cost patients and their characteristics in Finland.

Authors:  Leena K Saastamoinen; Jouko Verho
Journal:  Eur J Health Econ       Date:  2012-05-12

4.  Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality.

Authors:  T L Jørgensen; J Hallas; S Friis; J Herrstedt
Journal:  Br J Cancer       Date:  2012-02-21       Impact factor: 7.640

5.  Counting drugs to understand the disease: the case of measuring the diabetes epidemic.

Authors:  Henrik Støvring; Morten Andersen; Henning Beck-Nielsen; Anders Green; Werner Vach
Journal:  Popul Health Metr       Date:  2007-02-21

6.  Intranasal Pregabalin Administration: A Review of the Literature and the Worldwide Spontaneous Reporting System of Adverse Drug Reactions.

Authors:  Mohamed Elsayed; René Zeiss; Maximilian Gahr; Bernhard J Connemann; Carlos Schönfeldt-Lecuona
Journal:  Brain Sci       Date:  2019-11-13

Review 7.  Core concepts in pharmacoepidemiology: Measures of drug utilization based on individual-level drug dispensing data.

Authors:  Lotte Rasmussen; Björn Wettermark; Douglas Steinke; Anton Pottegård
Journal:  Pharmacoepidemiol Drug Saf       Date:  2022-08-11       Impact factor: 2.732

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.